Arrowhead Pharmaceuticals

Yahoo Finance • 5 days ago

How Do Sarepta (SRPT)’s Enhanced Safety Moves Reflect Its Approach to Long-Term Risk Management?

Earlier this week, Sarepta Therapeutics received FDA approval to begin dosing non-ambulant Duchenne muscular dystrophy patients in Cohort 8 of the ENDEAVOR study, evaluating an enhanced immunosuppression regimen with Elevidys, and announce... Full story

Yahoo Finance • 6 days ago

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index easing 0.1% PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 6 days ago

Stocks making the biggest moves midday: Dell, Arrowhead Pharmaceuticals, Urban Outfitters & more

Check out the companies making the biggest moves midday: Arrowhead Pharmaceuticals — The stock popped 19% after the biopharmaceutical company reported fiscal year revenue that beat analyst expectations. Arrowhead's top line for the period... Full story

Yahoo Finance • 7 days ago

Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ...

This article first appeared on GuruFocus. Release Date: November 25, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR)... Full story

Yahoo Finance • 7 days ago

Arrowhead outlines REDEMPLO expansion with $60,000 annual price and expects top-line SHASTA-3/4 data in Q3 2026

Earnings Call Insights: Arrowhead Pharmaceuticals (ARWR) Q4 2025 MANAGEMENT VIEW * Dr. Christopher Anzalone, CEO, announced Arrowhead’s first FDA approval for REDEMPLO, marking a major milestone as the company transitions to a commerci... Full story

Yahoo Finance • 7 days ago

Arrowhead Pharmaceuticals GAAP EPS of -$0.01 in-line, revenue of $829.45M beats by $72.01M

* Arrowhead Pharmaceuticals press release [https://seekingalpha.com/pr/20320479-arrowhead-pharmaceuticals-reports-2025-fiscal-year-end-results] (ARWR [https://seekingalpha.com/symbol/ARWR]): FY GAAP EPS of -$0.01 in-line. * Revenue of... Full story

Yahoo Finance • 7 days ago

After-Hours Earnings Report for November 25, 2025 : ADSK, WDAY, ZS, DELL, HPQ, NTAP, NTNX, ARWR, URBN, AMBA, CLSK, PD

The following companies are expected to report earnings after hours on 11/25/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Autodesk, Inc. (ADSK)is reporting for the quarter ending October 31, 2025. Th... Full story

Yahoo Finance • 7 days ago

Here are the major earnings after the close Tuesday

Major earnings expected after the bell on Tuesday include: * Dell Technologies (DELL [https://seekingalpha.com/symbol/DELL]) * HP (HPQ [https://seekingalpha.com/symbol/HPQ]) * Zscaler (ZS [https://seekingalpha.com/symbol/ZS]) * Wo... Full story

Yahoo Finance • 8 days ago

Arrowhead Pharmaceuticals FQ4 2025 Earnings Preview

* Arrowhead Pharmaceuticals (ARWR [https://seekingalpha.com/symbol/ARWR]) is scheduled to announce FQ4 earnings results on Tuesday, November 25th, after market close. * The consensus EPS Estimate is -$0.16 [https://seekingalpha.com/sym... Full story

Yahoo Finance • 14 days ago

Sector Update: Health Care Stocks Rise Late Afternoon

Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Heal PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 14 days ago

Arrowhead rises as FDA approves lead drug for rare disorder

[US Food and Drug Administration (FDA)] Shares of Arrowhead Pharmaceuticals (ARWR [https://seekingalpha.com/symbol/ARWR]) gained on Tuesday after the U.S. FDA approved its lead asset Redemplo (plozasiran) for adults with a rare genetic di... Full story

Yahoo Finance • last month

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

PASADENA, Calif., October 21, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that a global licensing and collaboration agreement with Novartis, previously announced on September 2, 2025, has now close... Full story

Yahoo Finance • 2 months ago

Facioscapulohumeral Muscular Dystrophy Analysis Report 2025-2035: Market to Advance Rapidly, Driven by Breakthroughs in Genetic Research, Gene Therapy, and CRISPR-Based Therapeutic Innovations

Company Logo Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetic disorder marked by muscle weakness, primarily in the face, shoulders, and arms. The DUX4 gene mutation leads to toxic protein production, damaging muscle cells. FSHD... Full story

Yahoo Finance • 3 months ago

7 Biotech Stocks Trading At 52-Week Highs - Can The Rally Continue?

(RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a battle between our patience and our impul... Full story

Yahoo Finance • 3 months ago

Arrowhead sues Ionis over patent dispute related to lead asset

[Patent] JLGutierrez Arrowhead Pharmaceuticals (NASDAQ:ARWR [https://seekingalpha.com/symbol/ARWR]) sued Ionis Pharmaceuticals (NASDAQ:IONS [https://seekingalpha.com/symbol/IONS]) in a Delaware District Court on Wednesday as part of a pat... Full story

Yahoo Finance • 3 months ago

H.C. Wainwright Reiterated a Buy on Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 2, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Arrowhead Pharmaceuticals, Inc.... Full story

Yahoo Finance • 3 months ago

Medpace Holdings, Inc. (MEDP): A Bull Case Theory

We came across a bullish thesis on Medpace Holdings, Inc.  on Rocky&Turner’s Substack by James Emanuel. In this article, we will summarize the bulls’ thesis on MEDP. Medpace Holdings, Inc. 's share was trading at $475.51 as of August 29th.... Full story

Yahoo Finance • 3 months ago

Alphabet, Apple Stock Soars After Judge Says Chrome Sale Not Required

This article first appeared on GuruFocus. Sep 3 - Alphabet (NASDAQ:GOOGL) jumped on Wednesday, rising more than 7%, as investors reacted to a favorable antitrust ruling. A federal judge decided Google would not be forced to divest its Chr... Full story

Yahoo Finance • 3 months ago

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

- Upon closing, Arrowhead will receive an upfront payment of $200 million - Novartis will receive an exclusive worldwide license to ARO-SNCA, Arrowhead’s preclinical stage siRNA therapy for the treatment of synucleinopathies, such as Park... Full story

Yahoo Finance • 3 months ago

Mizuho maintains Sarepta Therapeutics stock rating, lowers Elevidys sales forecast

Investing.com - Mizuho maintained its Neutral rating and $19.00 price target on Sarepta Therapeutics (NASDAQ:SRPT) following the company’s second-quarter 2025 earnings report and debt refinancing. The stock, currently trading at $20.22,... Full story